IL2 and COVID-19: Compared to those derived from SEVERE COVID-19 patients, exosomes derived from MILD COVID-19 patients were more efficient in stimulating CD4+ T-cell activation and proliferation, with an induction of interleukin-2 (IL-2) secretion in vitro, which could trigger a rapid resolution of the disease in vivo.